美国 · SEC FORM 4
Enovis CORP
ENOV · NYSE · CIK 0001420800 · Healthcare · Medical Devices
内部人信号
2 位买方 · 9 条买入交易行 · $541.7K 买入总额
为什么有这个信号?
评分构成
每条进度条表示其对当前分数的贡献;权重和公式保持不变。
哪些因素限制了当前分数?
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ 角色得分低 · 买入者中职位最高的是:Chief Executive Officer(CEO、董事长和持股 10% 以上的股东得分最低)
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 6 additional owner(s) remain in Form 4 申报证据.
买方广度与集中度
Roles in the peak window: Chief Administrative Officer, Chief Executive Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 57.3
- 57.2
- 57.1
- 56.9
- 56.7
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -3.9%
- 3M
- -32.6%
- 6M
- -27.6%
- 12M
- -44.3%
波动率与流动性
- 波动率
- 55.6%
- Beta
- —
- 平均每日成交额
- USD 26.0M
估值
- 市值
- USD 1.0B
- P/E
- —
基本面
- 利润率
- -52.7%
- ROE
- -79.5%
- 细分行业
- Medical Devices
市场数据
价格数据截至:2026-10-11 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, 利润率, ROE · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-07-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 10,561,633
- 上期报告
- 9,483,247
- 日均成交量
- 1,836,233
- 回补天数
- 5.8
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 2,660 | USD 18.80 | USD 50,008 | SEC 申报 ↗ |
| 2026-09-04 | McDonald Damien | 买入 (P) | Common stock, par value $0.001 | 13,035 | USD 19.15 | USD 249,620 | SEC 申报 ↗ |
| 2026-09-03 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 5,140 | USD 19.46 | USD 100,024 | SEC 申报 ↗ |
| 2026-09-02 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 2,458 | USD 20.32 | USD 49,947 | SEC 申报 ↗ |
| 2026-06-15 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 20.92 | USD 20,920 | SEC 申报 ↗ |
| 2026-06-11 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,200 | USD 21.62 | USD 25,948 | SEC 申报 ↗ |
| 2026-06-10 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.00 | USD 23,000 | SEC 申报 ↗ |
| 2026-06-01 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 22.22 | USD 22,220 | SEC 申报 ↗ |
| 2026-03-13 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.74 | USD 23,740 | SEC 申报 ↗ |
| 2026-03-10 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.93 | USD 23,930 | SEC 申报 ↗ |
| 2026-03-09 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.39 | USD 23,390 | SEC 申报 ↗ |
| 2026-03-06 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 750 | USD 24.41 | USD 18,310 | SEC 申报 ↗ |
| 2026-03-04 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 250 | USD 25.10 | USD 6,275 | SEC 申报 ↗ |
| 2026-03-03 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 24.77 | USD 24,770 | SEC 申报 ↗ |
| 2026-02-27 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 25.50 | USD 25,500 | SEC 申报 ↗ |
Form 4 申报证据
65 transaction lines in the latest 365-day window; 519 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Ortiz Christine | 奖励/授予 (A) | Common stock, par value $0.001 | 958 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-04 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 2,660 | USD 18.80 | USD 50,008 | SEC 申报 ↗ |
| 2026-09-04 | McDonald Damien | 买入 (P) | Common stock, par value $0.001 | 13,035 | USD 19.15 | USD 249,620 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Ortiz Christine | 奖励/授予 (A) | Common stock, par value $0.001 | 958 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-04 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 2,660 | USD 18.80 | USD 50,008 | SEC 申报 ↗ |
| 2026-09-04 | McDonald Damien | 买入 (P) | Common stock, par value $0.001 | 13,035 | USD 19.15 | USD 249,620 | SEC 申报 ↗ |
| 2026-09-03 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 5,140 | USD 19.46 | USD 100,024 | SEC 申报 ↗ |
| 2026-09-02 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 2,458 | USD 20.32 | USD 49,947 | SEC 申报 ↗ |
| 2026-06-30 | Ortiz Christine | 奖励/授予 (A) | Common stock, par value $0.001 | 846 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-15 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 20.92 | USD 20,920 | SEC 申报 ↗ |
| 2026-06-11 | Engert Oliver | 奖励/授予 (A) | Common stock, par value $0.001 | 1,000 | USD 20.99 | USD 20,990 | SEC 申报 ↗ |
| 2026-06-11 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,200 | USD 21.62 | USD 25,948 | SEC 申报 ↗ |
| 2026-06-10 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.00 | USD 23,000 | SEC 申报 ↗ |
| 2026-06-01 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 22.22 | USD 22,220 | SEC 申报 ↗ |
| 2026-05-19 | Wienbar Sharon L | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Vinnakota Rajiv | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Shirley Brady | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | PERFALL A CLAYTON | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Ortiz Christine | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Okala Philip | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Lalor Angela S | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Kelly Liam | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-19 | Bodem Barbara W. | 奖励/授予 (A) | Common stock, par value $0.001 | 9,346 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-12 | McDonald Damien | 代扣税 (F) | Common stock, par value $0.001 | 12,634 | USD 25.99 | USD 328,358 | SEC 申报 ↗ |
| 2026-05-12 | BERRY PHILLIP BENJAMIN (BEN) | 代扣税 (F) | Common stock, par value $0.001 | 7,774 | USD 25.99 | USD 202,046 | SEC 申报 ↗ |
| 2026-03-13 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.74 | USD 23,740 | SEC 申报 ↗ |
| 2026-03-10 | Engert Oliver | 买入 (P) | Common stock, par value $0.001 | 1,000 | USD 23.93 | USD 23,930 | SEC 申报 ↗ |
| 2026-03-09 | VOGT LOUIS | 奖励/授予 (A) | Common stock, par value $0.001 | 36,247 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-09 | Tandy Bradley J | 奖励/授予 (A) | Common stock, par value $0.001 | 25,586 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-09 | ROSS TERRY D | 奖励/授予 (A) | Common stock, par value $0.001 | 36,247 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-09 | McDonald Damien | 奖励/授予 (A) | Common stock, par value $0.001 | 143,923 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-09 | Lang Patricia A | 奖励/授予 (A) | Common stock, par value $0.001 | 25,586 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-09 | KLECKNER JOHN | 奖励/授予 (A) | Common stock, par value $0.001 | 14,925 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | ENOV |
| CIK | 0001420800 |
| 行业 | Healthcare |
| 细分行业 | Medical Devices Yahoo Finance |
| SEC SIC | 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies |
| 交易所 | NYSE |
数据覆盖
| 本地 Form 4 历史 | 519 transaction lines from 2020-01-02 to 2026-09-30 30 P purchase lines · 131 S sale lines · 358 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.